ABSK131 / Abbisko - LARVOL DELTA

The MTA-Cooperative PRMT5 Inhibitor ABSK131 Exhibits Potent Activity and Broad Synergistic Potential in MTAP-Deleted Cancer Models (PRNewswire) - "Abbisko Therapeutics...announced that it has presented...late-breaking pre-clinical research posters at the 2025 AACR conference....Poster Number: LB427:...ABSK131 exhibits strong anti-tumor activity in MTAP-deleted lung and pancreatic cancer models and synergizes effectively with multiple therapeutic agents. These findings support the continued clinical development of ABSK131 as both a monotherapy and in combination regimens for MTAP-deleted cancers."

Late-breaking abstract • Preclinical • Lung Cancer • Pancreatic Cancer

The MTA-cooperative PRMT5 inhibitor ABSK131 exhibits potent activity and broad synergistic potential in MTAP-deleted cancer models (AACR 2025) - "ABSK131 exhibits strong anti-tumor activity in MTAP-deleted lung and pancreatic cancer models and synergizes effectively with multiple therapeutic agents. These findings support the continued clinical development of ABSK131 as both a monotherapy and in combination regimens for MTAP-deleted cancers."

Late-breaking abstract • Preclinical • Breast Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS • MAT2A • MTAP • PARP1

IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR, FROM THE CHINA CDE (HKEXnews) - "...Abbisko Therapeutics...announced that the Center for Drug Evaluation of the China National Medical Products Administration has cleared the IND application for ABSK131, a highly-selective small molecule inhibitor of PRMT5*MTA. Earlier in December 2024, ABSK131 received IND clearance from the U.S. FDA."

IND • New trial • Oncology

Heyu Pharmaceuticals' Potential Best-In-Class PRMT5*MTA Inhibitor Debuts at the 36th ENA Conference [Google translation] (bydrug.pharmcube.com) - "On October 23, Heyu Pharmaceuticals issued an announcement stating that the company's two preclinical research results were released at the 36th International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR conference...ABSK131 presented by Heyu Pharmaceuticals is a highly selective brain-accessible MTA-synergistic PRMT5 inhibitor, and its excellent properties support its rapid preclinical development...In in vitro experiments, ABSK141 showed high binding ability and good biochemical activity for KRASG12D. It also showed strong inhibitory effects on KRAS downstream signaling pathways and efficient anti-proliferation ability in a series of KRASG12D tumor cell lines. In vivo efficacy experiments also showed the strong anti-tumor ability of ABSK141 in multiple different KRASG12D tumor models."

Preclinical • Oncology

Preclinical characterization of ABSK131, a potential best-in-class MTA-cooperative PRMT5 inhibitor (EORTC-NCI-AACR 2024) - "ABSK131, presented here by Abbisko Therapeutics, is a highly selective MTA-cooperative and brain-penetrant PRMT5 inhibitor. Its superior profile supports its advancement into clinical studies."

Preclinical • Oncology • MTAP